Neurocrine publishes tardive dyskinesia scale validation research
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
April 29, 2026 4:05 PM EDTResearch published in The Journal of Clinical Psychiatry characterizes patient-reported improvement with INGREZZA® (valbenazine) capsules across the KINECT® clinical programPublication establishes a clinically meaningful improvement threshold for the Tardive Dyskinesia Impact Scale (TDIS)
SAN DIEGO, April 29, 2026 /PRNewswire/ -- Neurocrine... More
